Soluble Tumor Necrosis Factor Receptor 1 is Associated With Cardiovascular Risk in Persons With Coronary Artery Calcium Score of Zero
Main Article Content
Background: A coronary artery calcium (CAC) score of zero confers a low but nonzero risk of atherosclerotic cardiovascular events (CVD) in asymptomatic patient populations, and additional risk stratification is needed to guide preventive interventions. Soluble tumor necrosis factor receptors (sTNFR-1 and sTNFR-2) are shed in the context of TNF-alpha signaling and systemic inflammation, which play a role in atherosclerosis and plaque instability. We hypothesized that serum sTNFR-1 concentrations may aid in cardiovascular risk stratification among asymptomatic patients with a CAC score of zero.
Methods: We included all participants with CAC=0 and baseline sTNFR-1 measurements from the prospective cohort Multi-Ethnic Study of Atherosclerosis (MESA). The primary outcome was a composite CVD event (myocardial infarction, stroke, coronary revascularization, cardiovascular death).
Results: The study included 1471 participants (mean age 57.6 years, 64% female), with measured baseline sTNFR-1 ranging from 603 pg/mL to 5544 pg/mL (mean 1294 pg/mL ±378.8 pg/mL). Over a median follow-up of 8.5 years, 37 participants (2.5%) experienced a CVD event. In multivariable analyses adjusted for Framingham Score, doubling of sTNFR-1 was associated with a 3-fold increase in the hazards of CVD (HR 3.0, 95% CI: 1.48- 6.09, P = 0.002), which remained significant after adjusting for traditional CVD risk factors individually (HR 2.29; 95% CI: 1.04-5.06, P=0.04). Doubling of sTNFR-1 was also associated with progression of CAC >100, adjusted for age (OR 2.84, 95% CI: 1.33-6.03, P=0.007).
Conclusions: sTNFR-1 concentrations are associated with more CVD events in participants with a CAC score of zero. Utilizing sTNFR-1 measurements may improve cardiovascular risk stratification and guide primary prevention in otherwise low-risk individuals.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Pathogens and Immunity abides by Creative Commons BY 4.0:
This license lets others distribute, remix, tweak, and build upon your work for any lawful purpose, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. The authors maintain copyright of their materal.
*Due to a template error on our pdfs, articles published from May 20, 2016 to June 24, 2022 incorrectly state the copyright is held by Pathogens and Immunity. Copyright of all articles is held by the authors of each article as noted in the above copyright policy.
Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nature medicine. 2011;17(11):1410-1422. doi: 10.1038/nm.2538.
Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. Journal of the American College of Cardiology. 2009;54(23):2129-2138. doi: 10.1016/j.jacc.2009.09.009.
Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. Journal of the American College of Cardiology. 2007;49(21):2129-2138. doi: 10.1016/j.jacc.2007.02.052.
Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118(22):2243-2251, 4p following 2251. doi: 10.1161/CIRCULATIONAHA.108.814251.
Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine. 2008;359(21):2195-2207. doi: 10.1056/NEJMoa0807646.
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. The New England Journal of Medicine. 2017;377(12):1119-1131. doi: 10.1056/NEJMoa1707914.
Xanthoulea S, Pasparakis M, Kousteni S, et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. The Journal of Experimental Medicine. 2004;200(3):367-376. doi: 10.1084/jem.20040435.
Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101(18):2149-2153. doi: 10.1161/01.cir.101.18.2149.
Li XY, Hou HT, Chen HX, Wang ZQ, He GW. Increased circulating levels of tumor necrosis factor-like cytokine 1A and decoy receptor 3 correlate with SYNTAX score in patients undergoing coronary surgery. The Journal of International Medical Research. 2018;46(12):5167-5175. doi: 10.1177/0300060518793787.
McClelland RL, Chung H, Detrano R, Post W, Kronmal RA. Distribution of coronary artery calcium by race, gender, and age: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2006;113(1):30-37. doi: 10.1161/CIRCULATIONAHA.105.580696.
Zhang C, Xu X, Potter BJ, et al. TNF-alpha contributes to endothelial dysfunction in ischemia/reperfusion injury. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26(3):475-480. doi: 10.1161/01.ATV.0000201932.32678.7e.
Shareghi S, Ahmadi N, Young E, Gopal A, Liu ST, Budoff MJ. Prognostic significance of zero coronary calcium scores on cardiac computed tomography. Journal of Cardiovascular Computed Tomography. 2007;1(3):155-159. doi: 10.1016/j.jcct.2007.10.001.
Plank F, Friedrich G, Dichtl W, et al. The diagnostic and prognostic value of coronary CT angiography in asymptomatic high-risk patients: a cohort study. Open Heart. 2014;1(1):e000096. doi: 10.1136/openhrt-2014-000096.
Khan A, Arbab-Zadeh A, Kiani AN, Magder LS, Petri M. Progression of noncalcified and calcified coronary plaque by CT angiography in SLE. Rheumatology International. 2017;37(1):59-65. doi: 10.1007/s00296-016-3615-z.
Bild DE, Bluemke DA, Burke GL, et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. American Journal of Epidemiology. 2002;156(9):871-881. doi: 10.1093/aje/kwf113.
Burke G, Lima J, Wong ND, Narula J. The Multiethnic Study of Atherosclerosis. Global Heart. 2016;11(3):267-268. doi: 10.1016/j.gheart.2016.09.001.
Bluemke DA, Kronmal RA, Lima JAC, et al. The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. Journal of the American College of Cardiology. 2008;52(25):2148-2155. doi: 10.1016/j.jacc.2008.09.014.
Horiuchi T, Mitoma H, Harashima S ichi, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford, England). 2010;49(7):1215-1228. doi: 10.1093/rheumatology/keq031.
Kemp R, Dunn E, Schultz M. Immunomodulators in inflammatory bowel disease: an emerging role for biologic agents. BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 2013;27(6):585-590. doi: 10.1007/s40259-013-0045-2.
Ma X, Xu S. TNF inhibitor therapy for rheumatoid arthritis. Biomedical Reports. 2013;1(2):177-184. doi: 10.3892/br.2012.42.
Tobin AM, Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 2005;19(1):47-57. doi: 10.2165/00063030-200519010-00006.
Rus HG, Niculescu F, Vlaicu R. Tumor necrosis factor-alpha in human arterial wall with atherosclerosis. Atherosclerosis. 1991;89(2-3):247-254. doi: 10.1016/0021-9150(91)90066-c.
Wang S, Bray P, McCaffrey T, March K, Hempstead BL, Kraemer R. p75(NTR) mediates neurotrophin-induced apoptosis of vascular smooth muscle cells. The American Journal of Pathology. 2000;157(4):1247-1258. doi: 10.1016/S0002-9440(10)64640-8.
Kim HL, Lee JP, An JN, et al. Soluble Tumor Necrosis Factor Receptors and Arterial Stiffness in Patients With Coronary Atherosclerosis. American Journal of Hypertension. 2017;30(3):313-318. doi: 10.1093/ajh/hpw134.
McKellar GE, McCarey DW, Sattar N, McInnes IB. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nature Reviews Cardiology. 2009;6(6):410-417. doi: 10.1038/nrcardio.2009.57.
Makki K, Froguel P, Wolowczuk I. Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines. ISRN Inflammation. 2013;2013:139239. doi: 10.1155/2013/139239.
Albert MA, Glynn RJ, Ridker PM. Effect of physical activity on serum C-reactive protein. The American Journal of Cardiology. 2004;93(2):221-225. doi: 10.1016/j.amjcard.2003.09.046.
Li JH, Pober JS. The cathepsin B death pathway contributes to TNF plus IFN-gamma-mediated human endothelial injury. Journal of Immunology (Baltimore, Md : 1950). 2005;175(3):1858-1866. doi: 10.4049/jimmunol.175.3.1858.
Grisar J, Aletaha D, Steiner CW, et al. Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. Annals of the Rheumatic Diseases. 2007;66(10):1284-1288. doi: 10.1136/ard.2006.066605.
Gao X, Zhang H, Belmadani S, et al. Role of TNF-alpha-induced reactive oxygen species in endothelial dysfunction during reperfusion injury. American Journal of Physiology Heart and Circulatory Physiology. 2008;295(6):H2242-9. doi: 10.1152/ajpheart.00587.2008.
Corda S, Laplace C, Vicaut E, Duranteau J. Rapid reactive oxygen species production by mitochondria in endothelial cells exposed to tumor necrosis factor-alpha is mediated by ceramide. American Journal of Respiratory Cell and Molecular Biology. 2001;24(6):762-768. doi: 10.1165/ajrcmb.24.6.4228.
Quinn K, Henriques M, Parker T, Slutsky AS, Zhang H. Human neutrophil peptides: a novel potential mediator of inflammatory cardiovascular diseases. American Journal of Physiology Heart and Circulatory Physiology. 2008;295(5):H1817-24. doi: 10.1152/ajpheart.00472.2008.
Spinelli FR, di Franco M, Metere A, et al. Decrease of asymmetric dimethyl arginine after anti-TNF therapy in patients with rheumatoid arthritis. Drug Development Research. 2014;75 Suppl 1:S67-9. doi: 10.1002/ddr.21200.
Tam LS, Kitas GD, González-Gay MA. Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? Rheumatology (Oxford, England). 2014;53(6):1108-1119. doi: 10.1093/rheumatology/ket454.
Dzaye O, Dardari ZA, Cainzos-Achirica M, et al. Warranty Period of a Calcium Score of Zero: Comprehensive Analysis From MESA. JACC Cardiovascular Imaging. 2021;14(5):990-1002. doi: 10.1016/j.jcmg.2020.06.048.
Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary Calcium Score and Cardiovascular Risk. Journal of the American College of Cardiology. 2018;72(4):434-447. doi: 10.1016/j.jacc.2018.05.027.
Spoettl T, Hausmann M, Klebl F, et al. Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. Inflammatory Bowel Diseases. 2007;13(6):727-732. doi: 10.1002/ibd.20107.